BioNTech's June Gauntlet: ASCO Lung Cancer Data, a Board Overhaul, and Founders Mapping Their Exit

BioNTech presents pumitamig vs Keytruda Phase 2 data at ASCO on May 29, while AGM on May 15 votes on board expansion and €129.5M capital hike. Q1 net loss of €531.9M contrasts with €2B guidance.

The next three weeks will test whether BioNTech can convince investors its post-pandemic strategy has real traction. On May 29, the company will present Phase?2 data from the ROSETTA-Lung-02 study at the ASCO congress — a head-to-head trial in which its experimental bispecific antibody pumitamig, combined with chemotherapy, takes on the established standard of pembrolizumab (Keytruda) plus chemo in first-line non?small?cell lung cancer. The outcome will be an early gauge of whether pumitamig can challenge a blockbuster incumbent.

Just two weeks before that data drop, the virtual annual general meeting on May?15 will set the stage for a broader corporate reshuffle. Shareholders will vote on expanding the supervisory board from six to eight seats, adding two specialists in clinical development to oversee the succession of founders U?ur ?ahin and Özlem Türeci. The couple plans to leave BioNTech by the end of 2026 to launch a new mRNA spin?off, and a binding agreement between the company and its founders is expected to be signed in the first half of the year. BioNTech will grant the new venture rights and mRNA technologies at arm’s?length terms, receiving in return a minority stake, milestone payments, and royalties.

The AGM also covers a fresh capital authorisation: up to €129.5?million in new approved capital for 2026, equivalent to 50?% of the current share capital, replacing the 2025 mandate. A domination and profit?transfer agreement with the subsidiary BioNTech Discovery GmbH is on the table as well, designed to allow tax consolidation by offsetting the unit’s profits against the parent’s losses. Given BioNTech posted a net loss of €1.14?billion in the 2025 financial year, the move is more than a technicality. No dividend is proposed; the entire retained earnings of roughly €6.9?billion will be carried forward.

The financial strain is already visible in the books. First?quarter 2026 revenue came in at €118.1?million, down sharply from €182.8?million a year earlier, as COVID?19 vaccine sales continue to fade. The net loss for the period reached €531.9?million. Research?and?development spending climbed to €557?million, driven mainly by the oncology pipeline, with pumitamig and gotistobart absorbing the bulk of the outlay.

Despite the weak start, management reaffirmed the full?year revenue guidance of €2.0?billion to €2.3?billion — in dollar terms the range is $2.3?billion to $2.6?billion — implying a radical acceleration in the quarters ahead, likely from milestone payments and other project?linked income. The company also authorised a $1?billion share buyback programme to be executed over twelve months.

That gap between a loss?making first quarter and a billion?euro annual target explains the market’s edginess. The stock fell 5.3?% immediately after the Q1 release and closed at €78.95 on Monday, down 0.63?% on the day and 7.12?% on the week, slipping below its 50?day moving average of €82.70. At roughly €80, the share price now sits about 21?% below the 52?week high set in June 2025.

The traditional source of valuation comfort — the COVID?19 windfall — is giving way to a model that hinges entirely on clinical success. A recent fair?value estimate of $131.39 suggests roughly 40?% upside from current levels, but such models price in the expected value of the research programmes, not the current profit picture. That makes the stock vulnerable to disappointment but also creates a lever if the pipeline delivers.

BioNTech is simultaneously restructuring to fund its oncology pivot. It plans to cut 1,860 positions — a move that mirrors a broader sector trend in which about 40 biotech layoff rounds were recorded through April 2026 as companies trim costs to finance longer?term research. The job reductions are part of a deliberate resource shift out of the pandemic?era operations and into the cancer?focused business.

The next hard test for the pipeline will come at ASCO, and the company is not relying on pumitamig alone for lung?cancer ambitions. In April it struck a clinical collaboration with Boehringer Ingelheim to evaluate pumitamig in small?cell lung cancer, combining it with Boehringer’s DLL3/CD3 T?cell engager obrixtamig. If the upcoming head?to?head data can show a meaningful advantage over Keytruda?based therapy, the narrative around BioNTech’s transformation could shift quickly. If not, the market will need more evidence before it buys into the story.